go to contents

Proxygen GmbH

Back to list

Facts

Founded
2020
Staff
9
Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health

Profile

Proxygen harnesses the cellular protein quality control system to develop therapies against cancer and other life-threatening diseases. We are focused on particular small molecules called “molecular glue degraders” which mediate recruitment of a disease-causing protein to a ubiquitin ligase where it is ubiquitinated and directed to the proteasome for degradation. Hence, instead of merely blocking the function of harmful proteins, molecular glue degraders enable their complete and selective elimi

Similar companies in RDM biotech/pharma

Viravaxx AG

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

EURRUS Biotech GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Focus
human health
Details

APEIRON Cell Therapies GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Focus
human health
Details

ProComCure Biotech GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Cluster
ecoplus
Focus
human health
Details

Contact

Dr.-Bohr-Gasse 7
1030 Wien
Vienna

Contact:
Email: office@proxygen.com
Website